# Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

> **NCT03409081** · — · NO_LONGER_AVAILABLE · sponsor: **Astellas Pharma Global Development, Inc.**

## Conditions studied

- Acute Myeloid Leukemia (AML)
- FMS-like Tyrosine Kinase-3 (FLT3) Mutations

## Interventions

- **DRUG:** gilteritinib

## Key facts

- **NCT ID:** NCT03409081
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2018-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03409081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03409081, "Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03409081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*